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Abstract:
This is the last of a series of articles on invasive fungal infections prepared by opinion leaders in Turkey. The aim of these articles 
is to guide clinicians in managing invasive fungal diseases in hematological malignancies and stem cell transplantation based on 
the available best evidence in this field. The previous articles summarized the diagnosis and treatment of invasive fungal disease 
and this article aims to explain the risk categorization and guide the antifungal prophylaxis in invasive fungal disease.
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Özet:
Bu makale Türkiye’de invazif fungal enfeksiyon ile uğraşan uzmanlar tarafından hazırlanan bir seri yazının sonuncusudur. Bu 
makaleler hematolojik malignitelerde ve kök hücre nakli hastalarında invazif fungal hastalıkların yönetimini eldeki kanıtların 
ışığında en iyi hale getirmeyi amaçlamaktadır. İlk yazılar tanı ve tedaviyi özetlerken, bu makale invazif fungal hastalıkta risk 
kategorizasyonu ve profilaksiyi ele almaktadır.
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Introduction 
Dr. Murat Akova 
Invasive fungal diseases (IFDs) continue to be an important 
cause of morbidity and mortality during the course of disease 
in patients with hematological malignancies and/or stem 
cell transplantation [1]. The lack of a cheap, easily applied 
diagnostic test with high sensitivity and specificity, as well 
as the serious mortality caused by the delay in diagnosis, has 
brought prevention of fungal infections to the forefront. While 
recently developed effective new antifungal medications with 
a wide spectrum of activity make prophylactic application 
attractive in high-risk patient groups, the wide use of 
serological and molecular biological diagnostic tools, like 
high-resolution computerized tomography examinations, 
serum galactomannan and beta-D-glucan tests, and PCR 
applications provides effective treatment options for selected 
patients in the early period [2]. The most important concerns 
about prophylaxis are additional costs, unwanted side effects 
due to antifungal use, and development of resistance due to 
the use of unnecessary antifungal antibiotics in many patients 
in order to prevent fungal infection-related mortality in one 
patient. Therefore, before routine antifungal prophylaxis 
(AFP) is given to high-risk patient groups, the above-
mentioned risk-benefit relationship should be necessarily 
reviewed. If an example is to be given, in order to decrease 
infection incidence by 50%, the number of patients who 
should receive prophylaxis is 100 in an environment where 
fungal infection prevalence is 2%, and this figure drops to 44 
in the event that the prevalence is 4.5% [3]. Another point 
that should be kept in mind before application of prophylaxis 
is that although a decrease in fungal infection incidence 
and fungal-related mortality has been provided by AFP in 
numerous clinical studies performed to date, only 2 studies 
have been able to show a decrease in the general mortality of 
high-risk patients [4]. All these findings prove that selective 
action should be taken in high-risk patients regarding AFP.
Determination of Risk and Targets of Prophylaxis 
Dr. Fahir Özkalemkaş 
Patients with hematological malignancies and allogeneic 
stem cell transplantation are the primary risk groups for IFD 
[5,6]. It has been known for a long time that early treatment 
initiation in patients with IFD is one of the major determinants 
of successful treatment and decreased mortality [7,8,9]. 
Despite all the recent advances in diagnostic testing, the 
absence of rapid and reliable diagnostic tests in IFD diagnosis 
enhances the importance of risk determination. When the 
prevalence and mortality rates are taken into consideration, 
well-defined high-risk patients constitute the group that will 
benefit from the prophylactic use of an effective antifungal 
agent. Therefore, determination of the correct risk level forms 
the basis of AFP. Furthermore, besides an increase in mortality, 
IFDs lead to delays in scheduled treatments (chemotherapy, 
stem cell transplantation), longer hospital stays, and increased 
treatment costs [10,11,12,13].
Invasive aspergillosis and invasive candidiasis are the most 
important entities of IFD. A third important group is invasive 
mucormycosis infection, with a relatively low prevalence but 
a high mortality rate [5,6]. Apart from common risk factors 
such as neutropenia and long-term myelosuppression, risk 
profile varies depending on the causative agent. For example, 
while the presence of numerous spores in inspired air and 
factors facilitating the passage of these spores through 
respiratory mucous membranes and reduced phagocytosis 
in the tissues play the major role in aspergillosis infections, 
diminished general phagocytic activity, dense colonization in 
the gastrointestinal tract mucosa, and mucosal damage due 
to chemo-/radiotherapy come to the forefront in invasive 
candidiasis. For mucormycosis, in addition to defective 
phagocytosis, other factors such as prior steroid use and 
the presence of metabolic acidosis should also be taken into 
consideration [1,5,14,15].
Hematological malignancies are widely heterogeneous 
in terms of risk. Among patients with hematological 
malignancies, acute leukemia patients, particularly those with 
acute myeloid leukemia (AML) receiving remission induction 
chemotherapy, are at significantly higher risk [6,13]. High-
risk myelodysplastic syndrome (MDS) is treated similarly to 
AML, as both have similar biological behavior; hence, MDS 
patients receiving remission induction chemotherapy are 
accepted to have the same risk profile as AML patients [16]. 
Likewise, hematopoietic stem cell transplantation patients 
are also heterogeneous. Risk is especially lower in patients 
with autologous transplantation than in those with allogeneic 
transplantation. Among allogeneic stem cell recipients, risk is 
significantly increased in those with graft-versus-host disease 
(GVHD) and long-term steroid use [17]. Another point that 
should not be forgotten is that risk profile may change over 
time due to the use of new treatment agents. For instance, the 
use of new monoclonal antibodies may alter the risk profile 
of chronic lymphocytic leukemia patients who are considered 
to be at low risk [18]. Similarly, use of new protocols in both 
the preparative regimen and GVHD prophylaxis in allogeneic 
stem cell transplantation, different stem cell sources (bone 
marrow, peripheral blood, umbilical cord blood), donor type 
(unrelated donors, relatives with perfect or partial match), 
stem cell manipulation (T-cell reduction), and superimposed 
infections (cytomegalovirus, respiratory syncytial virus 
infections) may lead to remarkable changes in the risk profile 
[10,17,19,20,21,22,23,24,25].
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Apart from the comorbid conditions, the most important 
parameter in IFD development is neutropenia [26]. Both 
the depth and duration of neutropenia are important; more 
recently, an index taking these 2 parameters into account was 
reported to be important in predicting invasive mold infections 
[27]. In allogeneic transplants, in addition to neutropenia, 
development of long-term lymphopenia particularly enhances 
the risk of invasive aspergillosis [17]. 
Although specific polymorphisms (toll-like receptor 
4, plasminogen alleles, dectin-1, TNF-1A) in some genes 
affecting natural immunity have been reported in recent 
years to make significant changes in invasive aspergillosis 
risk, these parameters are far from practical for use in the 
determination of treatment approach [28,29,30,31,32,33]. A 
recent study demonstrated that genetic deficiency of pentraxin 
3 (PTX3) affects the antifungal capacity of neutrophils and 
may contribute to the risk of invasive aspergillosis in patients 
treated with hematopoietic stem cell transplantation [34].
Finally, in daily practice, particularly in Turkey, it is wise 
to underline the importance of environmental factors such 
as ‘air quality’ and personal factors like ‘colonization’ and 
‘prevention’ in risk determination. Causative molds in the 
air may be at different concentrations in different geographic 
regions and may show seasonal variations in the same region 
[1,20,35]. In this respect, positive-pressure HEPA filters can 
be of critical importance in reducing the risk in risky regions 
and periods. Colonization during hospitalization is considered 
among the risk factors [36]. Other environmental control 
measures, hand-washing being the leading one, may reduce 
the risk [37].
Timing of Prophylaxis 
Dr. Esin Şenol 
There is no standard approach or recommendation 
regarding the optimal timing of prophylaxis in the guidelines 
and prophylaxis protocols. It is understood from prophylaxis 
studies that prophylaxis initiation times are different: at the 
time of hospitalization, or at the beginning or at the end of 
chemotherapy. In 2 important studies on primary prophylaxis 
using posaconazole, AML or MDS patients receiving 
chemotherapy had prophylaxis initiated together with 
chemotherapy in those not using anthracycline or 24 h after 
anthracycline in those using anthracycline. It was planned 
to be continued until resolution of neutropenia (ANC>500/
mm3), fungal infection development, or for 12 weeks [mean 
of 23 days (1-110 days, 29±21)]. In patients with allogeneic 
stem cell transplantation and GVHD, it was planned to be 
given at the time of development of acute GVHD of 2-4 degree 
or chronic disseminated GVHD at a dose of 1 mg/kg/day for 
acute GVHD and 0.8 mg/kg every other day for chronic GVHD, 
or at the beginning of 2 or more immunosuppressive agents 
without steroids, and scheduled to be continued for 112 
days [38,39]. The reason for starting prophylaxis along with 
chemotherapy is that the oral antifungals used for prophylaxis 
reach their plasma saturation levels in the neutropenic period 
when fungal infection risk is the highest. This period is 5 days 
if voriconazole is used orally and 7-10 days if posaconazole 
is used [2,40,41]. However, there is concern that the azole 
antifungals mostly used for prophylaxis may interact with 
drugs used in chemotherapy regimens.
Fluconazole prophylaxis (not involving molds) is given 
to allogeneic stem cell transplantation recipients before 
engraftment, in the beginning or immediately after the 
preparative regimen. There is a strong recommendation for 
giving prophylaxis for at least 3-6 months after engraftment; 
however, this period can be prolonged if treatment-related 
immunosuppression is caused by drugs such as corticosteroids 
[42]. 
The single remarkable end-point for the timing 
of prophylaxis termination for autologous stem cell 
transplantation recipients and for patients receiving AML/MDS 
chemotherapy is the resolution of neutropenia. Additionally, 
prophylaxis is discontinued in the event of conditions like 
drug intolerance, development of a new fungal infection, and 
drug-related side effects. However, there are still uncertainties 
in the timing of termination as well as the timing of initiation of 
prophylaxis, especially in allogeneic stem cell transplantation 
recipients [43]. 
Agents Used in Prophylaxis 
Dr. Mehmet Sönmez 
Polyene, azole, and echinocandin-class antifungal 
agents, including fluconazole, itraconazole, posaconazole, 
voriconazole, micafungin, anidulafungin, caspofungin, 
amphotericin B deoxycholate, and liposomal amphotericin B, 
have been used for AFP [38,39,44,45,46,47,48,49,50,51,52]. 
Toxicity, drug interactions, costs, effects of the used antifungal 
agent on fungal diagnostic tests, and risk of developing 
resistant fungal infections should be taken into account in 
patients receiving antifungal prophylaxis. While a meta-
analysis of the studies comparing the efficacy of antifungal 
prophylaxis in patients receiving AML/MDS induction 
treatment or in those undergoing allogeneic hematopoietic 
stem cell transplantation showed that antifungal prophylaxis 
decreased IFD prevalence and IFD-related mortality, similar 
effects were not observed in patients undergoing autologous 
stem cell transplantation. The incidence of IFD, and especially 
the incidence of Aspergillus infections, was found to be lower in 
patients receiving prophylaxis for molds. However, side effect-
related discontinuation of the drug was found to be higher 
compared to the fluconazole-treated group. It was noted that 
that overall mortality was not changed [11,51,53]. Currently, 
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echinocandins, apart from micafungin and anidulafungin, 
and polyene-group antifungals are not considered to be 
preferable prophylactic agents in spite of their wide antifungal 
activity spectrum because of intravenous use, side effect 
profiles, costs, and absence of sufficient data on prophylactic 
use. Therefore, azole-group drugs are generally preferred in 
antifungal prophylaxis. Although itraconazole, included in 
this group of drugs, is an effective agent, high discontinuation 
rates due to gastric intolerance, drug interactions, and variable 
bioavailability restrict its use. Fluconazole, with the lowest rate 
of side effects and drug interactions and an activity spectrum 
limited to Candida species, is recommended in patients 
undergoing allogeneic hematopoietic stem cell transplantation 
during neutropenia, but necessitates mold testing during 
prophylaxis. The demonstration that posaconazole is more 
effective in preventing IFD development in comparison 
to fluconazole led to the preferential use of posaconazole 
prophylaxis in AML/MDS patients receiving induction 
treatment and in those who developed GVHD after allogeneic 
hematopoietic stem cell transplantation. However, the 
necessity of taking posaconazole on a full stomach along with 
food rich in fats, drug interactions, and the necessity of drug 
level monitoring are among the factors that restrict its usage. 
Likewise, while voriconazole, an azole-group drug that should 
be used in therapeutic levels, is recommended to be used in 
patients undergoing allogeneic stem cell transplantation, it 
requires careful monitoring of hepatotoxicity, neurotoxicity, 
and drug interactions [2,54,55,56,57,58,59,60]. Furthermore, 
voriconazole is recommended to be used for secondary 
prophylaxis in patients with prior Aspergillus infection who 
require retreatment or allogeneic hematopoietic stem cell 
transplantation. On the other hand, in hospitals with a mold 
incidence of <5% and with HEPA filtration, monitoring of 
patients with diagnostic tests without antifungal prophylaxis 
for molds may also be a suitable approach [60,61,62]. 
Monitoring of Prophylaxis 
Dr. Rabin Saba 
After a decision is made about AFP and the drug that 
will be used, the efficacy and side effects of the chosen 
drug should be monitored. Primarily, the interaction of 
the drug with food and other drugs should be evaluated. 
The bioavailability of voriconazole increases when taken 
on an empty stomach, itraconazole capsule with food, and 
posaconazole with fatty food. The bioavailability of proton 
pump inhibitors or H2 receptor blockers decreases when 
used together with posaconazole or itraconazole [2,63]. 
Considering drug interactions, special care should be taken 
when using triazoles, which can be both the substrate and the 
inhibitor of cytochrome P (CYP) 450 isoenzymes. Each drug 
should be considered individually. For instance, posaconazole 
is metabolized by glucuronidation, not by the CYP system; 
however, it is a weak inhibitor of CYP 3A4. For this reason, if 
taken together with drugs inducing CYP enzymes, the serum 
concentration of triazoles other than posaconazole decreases. If 
taken together with triazoles, the serum concentration of drugs 
metabolized by CYP enzymes increases. It is contraindicated 
to use sirolimus with voriconazole and posaconazole 
[64]. When interactions with chemotherapeutic agents 
are considered, the best known example is the interaction 
between itraconazole and vincristine [65]. The increased 
neurotoxicity (by crossing the blood brain barrier) and the 
organ toxicity of vincristine is noteworthy. Antifungal drugs 
should also be monitored in terms of side effects [66]. While 
triazoles are particularly monitored regarding tolerability 
and hepatotoxicity, amphotericin B should be monitored in 
terms of infusion-related side effects, nephrotoxicity, and 
hypokalemia. The point that should not be forgotten is that 
prophylaxis should be used in conditions where the protective 
effects of prophylaxis are superior to the expected side effects. 
Discontinuation of the drug and/or switching to another drug 
should be considered in the case of side effects. 
Drug Level Monitoring
While therapeutic drug monitoring generally gains 
importance for mold-active triazoles (itraconazole, 
voriconazole, and posaconazole), it is not recommended 
for echinocandin and polyene-group antifungals [2,63]. 
Measurement of serum concentrations is especially 
recommended in pharmacokinetically unstable patients 
(children, neonates, critical patients, those with organ 
dysfunction, etc.), in the suspicion of incompatibility, in 
the presence of drug interactions, when switching from the 
intravenous form of the drug to the oral form, and in patients 
with absorption problems such as diarrhea or GVHD. 
Itraconazole
The bioavailability of itraconazole is variable and shows 
changes depending on the formulation. Bioavailability of 
the oral capsules increases with food and gastric acidity. The 
oral solution, which has better bioavailability, is much better 
absorbed when taken on an empty stomach and is not affected 
by gastric acidity. As the rates of breakthrough infections and 
mortality were found to be significantly higher at lower drug 
levels, it is required to maintain the serum concentrations 
at >8 mg/L (measuring both itraconazole and hydroxy-
itraconazole levels) as measured by bioassay method, at 
<0.5-1 mg/L by high-performance liquid chromatography 
and mass spectrometry, and at <17 mg/L by bioassay to 
minimize gastrointestinal, neurological, and hepatic toxicity 
[67,68]. As the drug concentration will achieve a steady state 
within 2 weeks, the measurements should begin after 7 days 
[2,63,64,65,66,67,68]. 
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Voriconazole
As voriconazole shows nonlinear pharmacokinetics, 
changes in the dosage are not similarly reflected. Although 
the efficacy of prophylaxis monitoring has not been clearly 
demonstrated, serum concentrations are to be maintained at 
1-5 mg/L with regard to toxicity [63,69,70]. It is recommended 
that serum concentrations should be measured within and 
after 5 days of use.
Posaconazole
Due to its long half-life (34 h), and because the drug 
concentration achieves a steady state within 7 days, the first 
measurement is recommended to be performed after 1 week 
of use [63]. The plateau concentration is recommended to be 
>0.7 mg/L for efficient prophylaxis [63,71,72]. It was shown 
that the alveolar intracellular posaconazole level was 40-50 
times greater than outside the cell and this might explain 
the efficacy of posaconazole prophylaxis in patients with 
low serum posaconazole levels [73]. As the alveolar tissue 
concentration is important for posaconazole, it has been stated 
that alveolar concentration rather than serum concentration 
will be required to be measured in the future [63].
In the follow-up of patients receiving mold prophylaxis for 
fungal infections, special care should be given to diagnostic test 
interpretation. Notably, the sensitivity of the galactomannan 
test is decreased in patients receiving posaconazole and 
voriconazole prophylaxis [74]. A study evaluating the place 
of Aspergillus polymerase chain reaction and galactomannan 
antigen in bronchoalveolar lavage fluid in diagnosis showed 
that anti-mold prophylaxis decreases sensitivity [75]. On 
the other hand, there are studies reporting that itraconazole 
prophylaxis had no effect on the molecular method used 
[76]. Therefore, sensitivity of molecular tests should also be 
interpreted with caution [77,78].
Prophylaxis Failure 
Dr. Seçkin Çağırgan 
AFP failure may be defined as the development of 
proven or probable IFD during prophylaxis, the requirement 
of empirical antifungal treatment, and the necessity of 
discontinuing the prophylaxis drug due to side effects or 
patient-related reasons [39].
AFP failure due to development of an IFD may be 
related to the activity spectrum of the prophylactic agent, 
development of infection with resistant fungal pathogens, 
and failure to provide effective blood levels of the drug. 
Although fluconazole prophylaxis significantly reduces 
Candida infections in patients with acute myelocytic leukemia 
and in those undergoing allogeneic stem cell transplantation, 
it is accompanied with an increase in the rates of invasive 
aspergillosis and other mold infections, as fluconazole is not 
active against molds [39,42,44,79]. Moreover, it has been 
shown that fluconazole prophylaxis increases colonization and 
development of infection with resistant non-albicans Candida 
species [80,81]. The risk of aspergillosis decreases if a broad-
spectrum azole (itraconazole, voriconazole, or posaconazole) 
or an echinocandin effective against Aspergillus species 
is used; however, the probability of infections with other 
molds, especially Mucorales species, remains the same, as 
itraconazole, voriconazole, and echinocandins are not effective 
against Mucorales [82]. Failure in providing adequate serum 
levels is most frequently seen when using oral itraconazole 
and posaconazole and this may lead to prophylaxis failure 
and development of an IFD [2]. Particularly, patients with 
mucositis, nausea and vomiting, insufficient enteral intake, 
and diarrhea are at risk. 
Necessity of termination of prophylaxis or switching to 
another drug may be associated with patient intolerance or 
drug toxicity. Gastrointestinal intolerance and hepatotoxicity 
are the most common toxicity-related causes of AFP 
termination [2]. 
Prophylaxis using mold active agents, posaconazole being 
the leading one, has been demonstrated to significantly decrease 
the sensitivity of galactomannan testing [83,84]. Therefore, a 
preemptive AFP treatment approach based on galactomannan 
antigen monitoring will not be safe in these patients; hence, an 
empirical treatment approach is recommended.
A detailed diagnostic study should be started in 
patients with prophylaxis failure if symptoms and clinical 
findings indicative of an IFD are present. If possible, the 
pathogen should be detected (microscopic examination in 
suitable samples, culture, histopathological examination; 
bronchoscopy, galactomannan testing in bronchoalveolar 
lavage fluid in the presence of a pulmonary lesion, etc.) [2].
Which antifungal agent should be selected in AFP failure 
characterized by IFD development or the requirement of 
initiating empirical fungal treatment? As a general rule, a 
change in the antifungal agent class should be considered if an 
IFD is suspected [2]. The majority of cases with prophylaxis 
failure are associated with the development of pulmonary 
infiltrates. During oral mold-active azole prophylaxis, 
switching to liposomal amphotericin B should be considered 
if aspergillosis is suspected (galactomannan positivity) and 
effective serum levels of itraconazole or posaconazole can be 
achieved or if drug level monitoring is not available [2,82]. 
If low serum levels of itraconazole or posaconazole have 
been shown, intravenous voriconazole can be used [2]. If 
galactomannan antigen testing is negative or is not available 
and a mold-active azole or echinocandin effective against 
Aspergillus strains has been used in prophylaxis, the risk 
of Aspergillus infection decreases; however, the probability 
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of infections with other filamentous fungi, particularly 
Mucorales, remains, as itraconazole, voriconazole, and 
echinocandins are not effective against Mucorales strains. 
Posaconazole is active against some Mucorales strains; 
however, effective serum concentrations usually cannot be 
achieved. In these conditions, liposomal amphotericin B, with 
the widest spectrum of activity (Candida, Aspergillus species, 
Cryptococcus, Fusarium, Mucorales, and endemic fungi), is the 
antifungal drug that should be chosen. 
Azoles should not be used empirically in the case of prior 
azole prophylaxis [58].
Secondary Prophylaxis 
Dr. Mehmet Ali Özcan 
During cytotoxic treatment, there is a substantial risk of 
recurrent invasive fungal infection in patients who “survived” 
the first invasive fungal infection. This rate is between 16% 
and 33% in the published series and IFD-related mortality 
reaches up to 88% [85,86,87,88,89]. Application of antifungal 
drugs for the management of this risk is called “secondary 
prophylaxis”. The most important problem in this area is that 
there is still no prospective randomized study on this subject. 
Therefore, evaluations are based on available experiences 
with different applications of antifungal agents. Amphotericin 
formulations, fluconazole, itraconazole, caspofungin, 
voriconazole, and posaconazole can be used in secondary 
prophylaxis depending on the use and success of these 
agents in primary treatment [90] (Table 1). While secondary 
prophylaxis seems to be effective according to the information 
obtained from case series and the few prospective secondary 
prophylaxis studies published to date, sufficient evidence to 
make a recommendation on the use of “which agent”, “what 
dose”, and “for how long” has not yet been provided. 
In manuscripts evaluating secondary prophylaxis, probable 
risk factors, mainly neutropenia duration, state of underlying 
disease, presence of GVHD, and steroid use, are found to be 
important.
The European Conference on Infections in Leukemia 
guidelines recommend secondary prophylaxis with an 
evidence level of AII, and, instead of recommending a certain 
agent, they recommend that secondary prophylaxis should 
be based on the causative agent of the prior invasive fungal 
infection and treatment success [58]. 
Table 1. Studies on secondary prophylaxis for invasive fungal diseases (IFDs).
Source Study The numbers and 
Characteristics of 
the Patients 
Drug Treatment 
Duration
new  
Breakthrough 
IFD
Sevilla et al. 
[91]
Case series 7 acute leukemia Itraconazole + liposomal 
amphotericin
4-22 months 0/7
Nosari et al. 
[92]
Case series 24 patients; 9 patients 
allo, 15 patients acute 
leukemia
Itraconazole; itracon-
azole + liposomal am-
photericin
Not indicated 3/24
Krüger et al. 
[93]
Case series 43 allo Liposomal amphoteri-
cin B
2-54 days 0/43
Cornely et al. 
[85]
Prospective 
survey
124 patients, 14.5% 
surgical resections
Miscellaneous;
itraconazole, 
voriconazole, liposomal 
amphotericin
Not indicated 26/124
Zhang et al. 
[94]
Retrospective 49 patients; 25 ALL, 
10 AML
Miscellaneous; 
voriconazole, itracon-
azole, caspofungin, lipo-
somal amphotericin
Not indicated 9/49
Cordonnier et 
al. [95]
Prospective 
open
45 patients Voriconazole, 400 mg/
kg/day
5-180 days 2/45
IFD: Invasive fungal disease.
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In the decision-making period of secondary prophylaxis, 
the selected patients with sequel lesions are to be evaluated in 
terms of receiving chemotherapy or surgical resection before 
transplantation. As this group of patients is small in number 
in case series, it would be suitable to evaluate this subgroup 
separately in clinical studies.
Environmental Protection
Dr. Can Boğa 
The basic principle in AFP is to use drugs with proven 
efficacy and high evidence levels. This section of the article 
mainly discusses subjects associated with environmental 
factors. 
Table 2. Recommendations of the CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC) [100].
Recommendations for Increasing Air Quality                                                                                                           
Evidence Level*
Use of heating, pressure, and ventilation filters 
Environmental monitoring 
Use of portable HEPA filters 
Providing back-ups for technical problems such as power source 
Obtaining tissue biopsies and culture samples for diagnosis, in case of Aspergillus or other respiratory 
nosocomial infection 
Taking necessary preventive precautions during construction (barriers, stoppers, portable HEPA filters, etc.)
Shortening the exposure time to fungal spores in transplant patients 
Maintenance of preventive measures when the patients leave their rooms for interventional procedures 
Maintaining positive pressure with respect to corridors 
Patient must be placed in a protective environment room with an anteroom
Category 1B
Category 1B 
Category 2 
Category 1C 
Category 1B 
Category 1B 
Category 1B 
Category 1B 
Category 1B 
Category 1C 
Recommendations Related to Water Systems 
Prevention of damage to underground water pipes and contamination of water by soil 
Elimination of contaminated reservoirs 
Disinfection of sinks and taps 
Use of barrier precautions (gloves) in order to prevent the spread of infection after hand-washing 
Maintaining the temperature of hot water at >51 °C and cold water at <20 °C 
Periodically increasing the temperature of water to at least 66 °C 
Chlorination of water 
Disinfection of water tanks 
Category 1B
Category 1B
Category 2
Category 1A
Category 1C
Category 2
Category 1C
Category 2
Other Environmental Precautions
Scrubbing the non-critical surfaces with detergents 
Regular scrubbing of ceilings, floors, and walls 
Not performing alcohol disinfestation on large surfaces 
Use of registered ready-to-use disinfectants 
Deep vacuum cleaning of the carpets and wool fabrics 
Avoiding the use of carpets in high-traffic zones 
Using carpeting in dry places (in order to avoid fungal growth), not keeping carpets in wet places for over 72 h 
Restriction of flowers 
Staff should be instructed to wear gloves when handling plants and flowers; negative pressure should be 
provided in the areas with dirty laundry 
Minimizing contact with saliva, urine, and feces of animals 
Hand-washing after contact with an animal
Implementation of waste control procedures
Category 2
Category 2
Category 2
Category C
Category 2
Category 2
Category 1B
Category 2
Category 2
Category 1C
Category 2
Category 2
 
*: Good Manufacturing Practice recommendations are taken into account. Category 1A: Strongly recommended for implementation and strongly supported by well-designed 
experimental, clinical, or epidemiologic studies. Category 1B: Strongly recommended for implementation and supported by certain experimental, clinical, or epidemiologic 
studies and a strong theoretic rationale. Category 1C: Required by state or federal regulation or representing an established association standard. Category 2: Suggested for 
implementation and supported by suggestive clinical or epidemiologic studies, or a theoretic rationale. 
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Nosocomial fungal infections are mainly transmitted by 
air, and less frequently by the oral route. It is well known 
that hospital construction and repair activities may increase 
the fungal spore concentrations in the air and that they are 
associated with the frequency of IFDs [96,97]. 
Organizations That Recommend the Use of HEPA Filters 
in Critical Areas 
Areas such as bone marrow transplantation units, in which 
immunosuppressed patients that require protection from 
infectious agents are monitored, and the isolation areas in 
which infected patients are monitored are defined as critical 
areas. The US Centers for Disease Control and Prevention 
(CDC) and the Spanish Society of Infectious Diseases and 
Clinical Microbiology recommend that these areas should 
be separated from other areas; heating, water systems, and 
ventilation conditions should be specially organized; and 
HEPA filters changing the room air 12 times in an hour should 
be used (Table 2) [98]. 
In What Conditions Are HEPA Filters Effective?
The minimum acceptable limits that can lead to the 
development of IFDs are debatable. It is required that HEPA 
filters should remove the respirable particles from the 
environment at least at the Good Manufacturing Practices 
Class D level (Table 3). It was demonstrated in a Spanish 
study that if the limit for the room air is 0.5 CFU/m3, or in 
other words if the presence of 1 fungus colony in 2 m3 of air 
is allowed, it can lead to infections in high-risk patients [97].
Evaluations of the Outcomes of HEPA Filter Use
The results of published studies on HEPA filters are 
summarized as follows [98,99,100,101,102,103,104,105]:
a. HEPA filters are effective to reduce the fungal load in the 
room air during and after construction.
b. HEPA filters were found to provide a more effective 
protection against invasive aspergillosis than amphotericin B 
during and after construction. 
c. Acceleration of the laminar flow increases the efficacy of 
HEPA filters. Fungal concentration in the air is correlated with 
a decrease in IFD incidence. 
d. Moreover, HEPA filters were shown to improve the 
general quality of life after transplantation.
The Efficacy of Portable HEPA Filters 
The CDC recommends the use of portable HEPA filters 
with rates of 300-800 cubic feet per minute to improve the 
removal process of respirable particles (Category 2). HEPA 
filters may be placed at different locations in and out of the 
room during and after construction until the surfaces are 
completely cleaned (Category 2). Microbiological analysis of 
the air samples during and immediately after construction is 
not recommended [98,99,100]. 
Problematic Issues
Issues like patient-related comorbid conditions, the degree 
of immunosuppression, AFP, and microbiological quality of 
the water make it difficult to make scientific inferences. It 
has been reported that the gravity air-setting plate method is 
an applicable method in aerobiological monitoring of fungal 
spores. Petri plates involving Sabouraud agar media are placed 
in different areas of the rooms for 1 h with their lids open and 
each test is repeated 3 times. The samples are kept at 37 °C 
for 7 days. 
Quality Control
The necessary protective precautions during transfer of the 
patients, primarily the hand-washing of the health care staff, 
and the necessary arrangements in terms of hygiene, waste 
control, and biosafety increase the efficacy of environmental 
control. 
Antifungal Vaccines 
Dr. Zahit Bolaman 
Aggressive chemotherapy or the use of agents leading 
to lymphocyte dysfunction such as rituximab and Campath 
and GVHD-related immunosuppression negatively affect the 
previous immunity achieved by vaccines in hematological 
malignant diseases [106]. As the risk for pneumococcal infection 
increases, patients are recommended to receive pneumococcal 
conjugate (PCV13) vaccine or pneumococcal polysaccharide 
vaccine (PPV23) before or during chemotherapy [107]. For 
inactivated influenza, hepatitis A, hepatitis B, meningococcus, 
conjugate haemophilus influenza, diphtheria-tetanus-
pertussis, human papilloma, and poliovirus vaccinations, the 
country’s vaccination program is taken into account. It is not 
recommended that acute leukemia patients under induction, 
consolidation, or maintenance treatment or those receiving 
rituximab or alemtuzumab be vaccinated with any vaccine 
other than pneumococcal vaccine. Live vaccines including 
measles-mumps-scarlet fever, shingles, chicken pox, and polio 
are contraindicated before or during chemotherapy [108].
The immune system is reorganized after allogeneic stem cell 
transplantation. Vaccination with PCV13 or PPV23, inactivated 
Table 3. Clean room classification arranged according to 
the number of particles considering the particle size [100].
Class Particle Diameter 
(>0.5 µm)
Particle Diameter 
(>5 µm)
A 3520 20
B 35,200 29
C 352,000 2900
D 3,520,000 29,000
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influenza, hepatitis A and B, conjugate haemophilus influenza 
B, diphtheria-tetanus-pertussis, conjugate meningococcus, or 
inactivated polio is recommended to be performed at 3-12 
months after transplantation. General rules apply for the 
human papilloma virus vaccine. Live measles-mumps-scarlet 
fever vaccine is applied if the patient is seronegative, does 
not have GVHD, and is not receiving immunosuppressive 
treatment. Attenuated live influenza, live measles, mumps 
and measles-varicella, BCG, live shingles, varicella, and 
shingles vaccines are contraindicated (Table 4, Figure 1). 
Data are insufficient for typhoid fever and cholera vaccines 
[60,108,109,110].
The aggressive therapies used in hematological malignancies 
cause tissue destruction and immunosuppression, sometimes 
resulting in death due to fungal infections. Although some 
patients benefit from antifungal prophylaxis, the results are 
not very satisfying and optimal antifungal treatment strategies 
can only rescue 50% of patients. This is also associated with 
high economic cost. As a result, novel approaches are needed. 
Antifungal vaccines are developed for this purpose and show 
their effect by stimulating humoral or cellular immunity and 
by dendritic cells. For the full-blown effect of an antifungal 
vaccine, it is important to develop them against common 
fungal antigens (universal vaccines) [111]. The targeted 
antifungal determinants and their mechanisms are shown 
in Table 4. Successful results have been achieved in animal 
studies on fungal cell determinants, mainly laminarin, cell 
surface antigen, or dendritic cell-mediated vaccination [112]. 
Experimental animal studies are on-going with vaccines 
developed against Aspergillus, Candida, Cryptococcus, and 
pneumocystis infections, and 3 studies are being carried 
out in humans on recombinant NDV-3. Although lack of 
standardization, reduced immunogenicity, and difficulties 
in the vaccination of immunosuppressive individuals reduce 
the development speed of fungal vaccines, initial studies are 
Table 4. Immunological properties of fungal vaccines.
Disease Vaccine Mechanism
Aspergillosis HKY (heat-killed S. cerevisiae cells)*
Laminarin-CRM197 conjugate*
AspF antigens
Cell-wall glucanase Crf1*
Incomplete information: Possibly related to 
the antifungal effect of protective CD4Th1 
antibodies
Candida Laminarin
Fba (fructose-biphosphate-aldolase)*
β-Mannan-peptide or protein conju-
gates
Candida albicans cell-surface protein 
HyR1*
Recombinant Als3* proteins*
Recombinant Sap2* proteins
Laminarin-CRM197 conjugate
Mdh-1p
Direct antifungal effect of CD4Th1 antibod-
ies
Direct effect of anti-fba antibodies
Opsonic, antibody-mediated
Anti-Hyr1p neutralizing antibodies
Antibodies developed due to Th17-Th1 
activity 
Antibodies neutralizing Sap activity 
Direct anti-Candida effect of anti-β-glucan 
antibody
Anti-Mdh-1p antibody
Cryptococcus Laminarin-CRM197 conjugate
GXM conjugate peptide mimotopes
Antibodies related to capsule structure and 
function
Opsonic anti-capsular antibodies 
 *: Universal.
Figure 1. Vaccination program after allogeneic stem 
cell transplantation (modified from the Report from the 
International Consensus Conference on Clinical Practice in 
Chronic Graft-versus-host disease) [110].
DTaP: Diphtheria-tetanus-attenuated pertussis vaccine
*Influenza vaccine is repeated each year.
B
            6               7            8              12             18 months
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Table 5. Pros and cons of antifungal prophylaxis.
Advantages of antifungal prophylaxis Problems with antifungal prophylaxis
The prevalence of IFD caused by Candida strains has been 
decreased with routine AFP.
There has been an increase in the prevalence of Aspergillus and 
non-albicans Candida strains with routine AFP. In particular, 
mucormycosis frequency has been shown to increase with broad-
spectrum azole prophylaxis [115,116].
The patients who will benefit from AFP can depend on the 
right classification of risk groups.
Risk factors and potentials for developing diseases are widely 
variable. Patients should be assessed individually for multiple 
factors; there are differences in the risk factors and classifications 
over time. 
There are many old and new drugs with proven efficacy that 
can be used in AFP.
The usage, doses, efficacies, and side effect profiles of these drugs 
are quite different from each other. 
In these patients, the frequently used drugs, mainly chemotherapy 
and immunosuppressive drugs, interact with many other drugs. 
Food may change the absorption rates of the drugs and there may 
be individual differences.
AFP has been shown to be beneficial in some high-risk 
patients with hematological malignancies or in those 
undergoing stem cell transplantation.
Low IFD incidence in certain patient groups, increased risk 
of toxicity and resistance, and increased treatment cost due to 
unnecessary AFP use prevents its routine use in all patients. Patient-
based risk-benefit evaluation should be performed.
Different drugs should be selected in patients according to 
the increased risk of developing yeast or mold infections. 
The number of randomized controlled trials (RCTs) in which head-
to-head comparisons of several drugs are made is limited. Therefore, 
recommendations with high levels of evidence cannot be made in 
various guidelines and different recommendations are available in 
different guidelines. Treatment failure rates with mold-active AFP 
in real-life studies are higher in comparison to those in registration 
studies [116,117,118,119]. 
Meta-analysis performed in 2007 [11]:
64 RCTs, AFP (fluconazole, itraconazole, posaconazole) 
versus placebo
Decreases in fungal-related mortality (RR: 0.66) and 
documented IFDs (RR: 0.69) were seen in acute leukemia 
patients. 
All-cause mortality (RR: 0.62), fungal-related mortality 
(RR: 0.52), and documented IFDs (RR: 0.33) decreased in 
allogeneic transplant patients.
Meta-analysis performed in 2007 [11]:
64 RCTs, AFP (fluconazole, itraconazole, posaconazole) versus 
placebo
No difference could be detected in all-cause mortality (RR: 0.88) in 
acute leukemia patients.
Meta-analysis performed in 2012 [53]:
20 RCTs, mold-active versus fluconazole
Fungal-related mortality (RR: 0.67), documented IFDs (RR: 
0.71), and invasive aspergillosis risk (RR: 0.53) in both 
acute leukemia and allogeneic transplant patients were 
decreased.
Meta-analysis performed in 2012 [53]:
20 RCTs, mold-active versus fluconazole
No difference could be detected in all-cause mortality in acute 
leukemia and allogeneic transplant patients. Side effects leading to 
drug discontinuation were more common in patients using mold-
active drugs (RR: 1.95).
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Table 5. Continuous
Advantages of Antifungal prophylaxis Problems with antifungal prophylaxis
Meta-analysis performed in 2014 [120]:
20 RCTs, stem cell transplantations
Risk of documented fungal disease (OR: 0.24), risk of 
systemic candidiasis (OR: 0.11), and overall need for empirical 
antifungal treatment (OR: 0.60) was decreased in patients 
receiving fluconazole in comparison to those receiving a 
placebo. 
Risk of invasive aspergillosis was lower in patients receiving 
itraconazole than in those receiving fluconazole (OR: 0.40). 
Risk of mold infections was found to be lower in those 
receiving micafungin than those receiving fluconazole (OR: 
0.35). 
Voriconazole was found to be superior to fluconazole and 
itraconazole, and posaconazole was found to be superior to 
amphotericin B.
Meta-analysis performed in 2014 [120]:
20 RCTs, stem cell transplantations 
IFD risk under AFP was 5.1%. 
Most of the studies were performed using fluconazole.
Comparative studies with new azoles are very limited (a single RCT).
GITMO guidelines published in 2014 [121]:
Allogeneic stem cell transplantation patients are divided into 3 
risk groups (high, standard, low) in 3 different periods (early, 
late, very late). Mold-active drugs are recommended in the 
high-risk group, and AFP is recommended in the standard-risk 
group.
Real-life data published in recent years [117]:
Posaconazole comes into prominence in AML and MDS patients and in 
transplant patients with GVHD; although the level of evidence is low as 
the studies were retrospective and comparisons were made with historic 
controls, these data are valuable as they reflect real life.
Fluconazole:
Oral + 4, cheap, good tolerability, fewer drug interactions.  
Echinocandin group:
Effective against most Candida species, safety profile is high 
and drug interaction is low. 
Itraconazole:
Effective against Aspergillus spp. 
Voriconazole:
Oral + 4, wide spectrum of activity, superior to fluconazole and 
itraconazole in AFP. 
Posaconazole:
Oral + 4, wide spectrum of activity. 
Liposomal amphotericin B:
A single high dose once a week, effective and safe in AML 
patients and children.
Fluconazole:
Anti-Candida spectrum is narrower than the candins, there is a risk of 
breakthrough infections (C. krusei, C. glabrata), not effective against 
molds. 
Echinocandin group:
Can only be used by 4 route, expensive.
Itraconazole:
Can only be used by oral route, low tolerability, variable bioavailability, 
high drug interactions. 
Voriconazole:
May lead to temporary visual impairment and hepatic toxicity, may 
interact with chemotherapy drugs.
Posaconazole:
Oral bioavailability is variable, may interact with chemotherapy drugs 
and proton pump inhibitors. 
Liposomal amphotericin B:
Studies involving small series. 
Drug level monitoring:
Used to increase treatment success and decrease side ef-
fects, is recommended for mold-active drugs (itraconazole, 
voriconazole, and posaconazole). 
Drug level monitoring:
Not in routine use in guidelines yet.
Timing of AFP:
AFP drugs that carry a risk of interaction with chemotherapy 
drugs are recommended to be discontinued 1 week before che-
motherapy and initiated after termination of chemotherapy. If 
not receiving AFP is a risk for the patient, echinocandin-group 
drugs or liposomal amphotericin B may be given in this period. 
Timing of AFP:
There is no clear standard on this issue; it may be necessary to continue 
it until neutrophil counts exceed 500/mm3 in leukemia patients and for 
at least 3 months in allogeneic transplants. If the patient is still at risk 
(immunosuppressive treatment, etc.), the period should be prolonged. 
Interaction with diagnostic antigen tests:
Drugs do not affect standardized PCR-based tests.
Interaction with diagnostic antigen tests:
Mold-active drugs (posaconazole, voriconazole) decrease the sensitivity 
of galactomannan test.
Secondary AFP:
The drug that is effective in the treatment of the first attack 
should be preferred.
Secondary AFP:
Risk of IFD extensively increases in the other chemotherapy periods of 
patients that had a previous IFD.
 
IFD: Invasive fungal disease, AFP: antifungal prophylaxis, GVHD: Graft-versus-host disease, AML: acute myeloid leukemia, MDS: myelodysplastic syndrome. 
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promising in decreasing deaths related to fungal infections by 
fungal vaccinations in the future [112,113,114].
Interpretation and Problematic Areas 
Dr. İhsan Karadoğan 
Although prophylaxis in IFDs has become more evidence-
based in recent years, there are still several gray areas and 
unresolved issues. A summary of these issues is presented in 
Table 5.
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